HER2-Low unbranded Adlob
More cancer patients may have a chance to treatment when a closer look at their IHC stains comes into play.
LC-NEC unbranded Adlob
For the first time, LC-NEC patients have a treatment made for them. The wait is finally over.
ADLOB FOR HER2+ DSE UNBRANDED CAMPAIGN
A promising treatment landscape for HER2+ cancer patients is on the horizon. Physicians will soon be able to stand defiant when facing HER2+ solid tumors.
ENHERTU DSE Campaign
Takeda Oncology
ADLOB FOR NEW BUSINESS - CORPORATE
Campaign to demonstrate Takeda’s commitment to research development in Oncology.
ADLOB FOR NEW BUSINESS - UNBRANDED
Ignyta® has developed a new treatment for cancer that targets a specific mutation known to cause several common cancers.
Ignyta
IGNYTA® PITCH REEL
Animation portraying different types of cancer and patients. The video concludes by showing how they are connected by a common mutation, treatable by a single drug developed by Ignyta®.
HCP ADLOB FOR NEW BUSINES
Adlob created to demonstrate Takeda’s commitment to oncology research and development.
Takeda Oncology
PATIENT ADLOB FOR NEW BUSINESS
The campaign capitalizes on the electrical charge produced by the Optune device and how its efficacy could be translated into a real patient benefit.
Optune
Sandoz Biosimilar
CORPORATE BIOSIMILAR CAMPAIGN
AAPI Awareness Campaign
PRO BONO INITIATIVE
GLOBAL PATIENT/HCP ADLOB FOR XEMPOZYME LAUNCH CAMPAIGN
This new treatment adds a missing enzyme characteristic of ASMD, therefore restoring the patients’ prospect to a more normal life.